One patient, one drug: custom gene therapy trial launches for Ultra-Rare disease
NCT ID NCT07223632
Summary
This is a highly personalized study for a single patient with a rare genetic nerve disease called CMT2S. The trial is testing the safety of a custom-made drug, VCA-894A, designed to fix a specific genetic error. The drug is injected into the spinal fluid to try to restore a missing protein and control the disease's progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMUSCULAR DISEASES (NMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanda Investigational Site
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.